Head-to-head evidence
ALX2004 vs BPI-361175
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
ALX2004
Developed by ALX Oncology Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT07085091 (registry estimate)
BPI-361175
Developed by Betta Pharmaceuticals Co.
NCT05329298 · Phase 1/2 · status unknown
This is an open-label, non-randomized phase 1/2 dose-escalation and expansion study in which every participant received BPI-361175 with no placebo or active comparator, and no blinding was used. Results have not been posted, and because the design never included a controlled comparison, it cannot demonstrate a controlled treatment effect regardless.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALX2004's landscape · BPI-361175's landscape